Nicotine pouches will be able to move more quickly through the US marketing authorisation process, following the launch of a pilot programme that acknowledges their place on the continuum of risk.
This move suggests the US is looking to embrace pouches as as its primary alternative nicotine product, in contrast to markets such as the UK. The UK’s scientific and regulatory consensus holds that e-cigarettes are the safest consumer nicotine product on the continuum of risk. UK guidance considers vaping less harmful than pouches or heated tobacco, although riskier than nicotine replacement therapies, like gums, patches and inhalers or pharmaceutical interventions.
